Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CGTX
CGTX logo

CGTX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cognition Therapeutics Inc (CGTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
1.290
1 Day change
9.41%
52 Week Range
3.830
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CGTX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near 1.18 with weak momentum, no clear bullish catalyst, no supportive insider or hedge fund activity, and no recent news flow. Given the lack of strong proprietary buy signals and the bearish near-term trend profile, the better call is to avoid initiating a long-term position now.

Technical Analysis

The technical picture is weak to neutral. Price is essentially flat around 1.18 and sitting just above the pivot at 1.182, which shows indecision rather than strength. MACD histogram is negative and expanding, signaling worsening momentum. RSI_6 at 45.7 is neutral, so there is no oversold rebound signal. Moving averages are converging, which typically reflects a lack of trend confirmation. Support is at 1.087 and 1.028, while resistance is at 1.278 and 1.337. The short-term trend estimate is also bearish, with expected weakness over the next week and month.

Positive Catalysts

  • No recent news in the past week. There are no reported positive event-driven catalysts, and trading data shows hedge funds and insiders are neutral. The only mild positive is that the stock is holding near pivot support, but that is not a strong catalyst.

Neutral/Negative Catalysts

  • No recent news flow, no strong hedge fund accumulation, no insider buying trend, and no AI Stock Picker or SwingMax buy signal. The technical setup is weak with negative MACD momentum, and the pattern-based trend outlook suggests downside over the next week and month. There is also no valuation or financial snapshot support to argue for a strong entry.

Financial Performance

Financial data was not available because the latest quarter snapshot returned an error, so there is no reliable quarter-over-quarter growth assessment to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data was provided, so there is no evidence of improving Wall Street sentiment. Based on the available information, the pros view is limited and the cons view dominates due to weak momentum, no catalysts, and no supportive trading activity.

Wall Street analysts forecast CGTX stock price to rise
2 Analyst Rating
Wall Street analysts forecast CGTX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.180
sliders
Low
3
Averages
3
High
3
Current: 1.180
sliders
Low
3
Averages
3
High
3
B. Riley
B. Riley
Buy
maintain
$2 -> $3
AI Analysis
2025-11-21
Reason
B. Riley
B. Riley
Price Target
$2 -> $3
AI Analysis
2025-11-21
maintain
Buy
Reason
B. Riley raised the firm's price target on Cognition Therapeutics to $3 from $2 and keeps a Buy rating on the shares. Cognition's Phase 2 START trial for early Alzheimer's has fully enrolled 540 patients, reinforcing momentum from prior positive Phase 2b results and rising investigator interest in oral zervimesine, the analyst tells investors in a research note. With an 18-month primary endpoint and allowance for combination therapy, the trial design offers meaningful de-risking ahead of a mid-to-late 2027 readout, the firm adds.

People Also Watch